Crohn's Disease: Symptoms, Causes, Management and Treatment

A special issue of Gastrointestinal Disorders (ISSN 2624-5647).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 4040

Special Issue Editor


E-Mail Website
Guest Editor
Division of Surgery, Department of Clinical And Experimental Medicine, University of Florence, AOU Careggi Hospital, 50139 Florence, Italy
Interests: inflammatory bowel diseases; endocrine surgery; general oncologic surgery; mini-invasive surgery

Special Issue Information

Dear Colleagues,

Chronic inflammation is a major risk factor for various human diseases. Inflammatory bowel diseases are the best abdominal example of this. Although many studies have focused on the steps of the inflammatory responses in the last several decades, further experiences are required for the effective understanding of the pathogenesis of this heterogeneous group of diseases. Moreover, there is a great need for studies able to clarify specific issues about clinical aspects of Crohn’s disease. This Special Issue aims to highlight the latest research about this topic. We invite researchers to contribute with original research, review articles, nonclinical studies and translational/clinical studies focusing not only on the roles of integrome but also on potential therapeutic targets for medical or surgical treatments.

Dr. Francesco Giudici
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastrointestinal Disorders is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel diseases
  • Crohn’s disease
  • surgery
  • gastroenterology
  • pathogenesis
  • therapy
  • integrome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

4 pages, 222 KiB  
Opinion
Crohn’s Disease: The infectious Disease Incorporated’s Perspective
by Gilles R.G. Monif
Gastrointest. Disord. 2021, 3(3), 138-141; https://doi.org/10.3390/gidisord3030015 - 25 Aug 2021
Cited by 2 | Viewed by 3185
Abstract
Infectious Diseases Incorporated (IDI) is an infectious disease think-tank, established in 1973. Crohn’s disease (CD) is a chronic, recurrent disease of the gastrointestinal tract that has reached epidemic proportions within industrialized nations. CD is said to be without cure. Since 2003, therapeutic interventions [...] Read more.
Infectious Diseases Incorporated (IDI) is an infectious disease think-tank, established in 1973. Crohn’s disease (CD) is a chronic, recurrent disease of the gastrointestinal tract that has reached epidemic proportions within industrialized nations. CD is said to be without cure. Since 2003, therapeutic interventions have focused on disruption of the pro-inflammatory Th1 response against an unknown antigen. In 2015, the Hruska Postulate was introduced and, in so doing, explained how, in the absence of acquired immunity, newborn infection by Mycobacterium avium subspecies paratuberculosis could cause fixation of the immune system’s Th1 response against the organism. The Hruska Postulate was utilized to answer all the documented epidemiological facts embedded in the natural history of Crohn’s disease and, in particular, why breastfeeding confers protection against the future development of Crohn’s disease. It is Infectious Diseases Incorporated’s (IDI) stated opinion that Crohn’s disease is both preventable and curable if treated appropriately in its early stages. Full article
(This article belongs to the Special Issue Crohn's Disease: Symptoms, Causes, Management and Treatment)
Back to TopTop